Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease.

Autor: Libiger O; Janssen Research and Development, San Diego, California, USA., Shaw LM; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Watson MH; Caprion Biosciences, Montreal, Quebec, Canada., Nairn AC; Yale University School of Medicine, New Haven, Connecticut, USA., Umaña KL; Foundation for the National Institutes of Health, North Bethesda, Maryland, USA., Biarnes MC; Foundation for the National Institutes of Health, North Bethesda, Maryland, USA., Canet-Avilés RM; Foundation for the National Institutes of Health, North Bethesda, Maryland, USA., Jack CR Jr; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Breton YA; Caprion Biosciences, Montreal, Quebec, Canada., Cortes L; Caprion Biosciences, Montreal, Quebec, Canada., Chelsky D; Caprion Biosciences, Montreal, Quebec, Canada., Spellman DS; Merck & Co., Inc., West Point, Pennsylvania, USA., Baker SA; Janssen Research and Development, Titusville, New Jersey, USA., Raghavan N; Janssen Research and Development, Titusville, New Jersey, USA., Potter WZ; National Institute of Mental Health, Bethesda, Maryland, USA.

Publikováno v: Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2021 Dec; Vol. 17 (12), pp. 1976-1987. Date of Electronic Publication: 2021 May 13.